A B-cell lymphoma vaccine using a depot formulation of interleukin-2 induces potent antitumor immunity despite increased numbers of intratumoral regulatory T cells

Cancer Immunology, Immunotherapy

Volumn 59, Issue 4, 2010, Pages 519-527

  Grille, Sofía ^a,b   Brugnini, Andreina ^a,b   Nese, Martha ^c   Corley, Esteban ^d   Falkenberg, Frank W ^e   Lens, Daniela ^a   Chabalgoity, José A ^b  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^b Universidad de la Republica Instituto de Higiene   (Uruguay)

^c HOSPITAL DE CLÍNICAS   (Uruguay)

^d PCgen   (Argentina)

^e Cires Cell and Immune Research Services GmbH   (Germany)

Author keywords

Aluminum hydroxide; Interleukin 2; Lymphoma; Regulatory t cells; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 4; RECOMBINANT INTERLEUKIN 2; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; FEMALE; GOOD MANUFACTURING PRACTICE; IMMUNE RESPONSE; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MOUSE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; TUMOR IMMUNITY; ANIMAL; B CELL LYMPHOMA; BAGG ALBINO MOUSE; CELL PROLIFERATION; FLOW CYTOMETRY; IMMUNOLOGY; PATHOLOGY; SURVIVAL RATE;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY;

EID: 77449115651     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0768-6     Document Type: Article

References (42)

1. Marcus R, Hagenbeek A (2007) The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol Suppl (67): 5-14 (Pubitemid 44934857)
2. Neelapu SS, Kwak LW (2007) Vaccine therapy for B-cell lymphomas: next-generation strategies. In: Gewirtz AM, Winter JN, Zuckerman K (eds) American Society of Hematology education program book. Atlanta, GA, pp 243-249
3. Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW (2006) Therapeutic lymphoma vaccines: importance of T-cell immunity. Expert Rev Vaccines 5(3): 381-394 (Pubitemid 44167159)
4. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327(17): 1209-1215
5. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 89(9): 3129-3135
6. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van BA, Levy R (2002) Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 62(20): 5845-5852 (Pubitemid 35204744)
7. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, Van BA, Liles TM, Engleman EG, Levy R (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99(5): 1517-1526 (Pubitemid 34533020)
8. Chabalgoity JA, Baz A, Rial A, Grille S (2007) The relevance of cytokines for development of protective immunity and rational design of vaccines. Cytokine Growth Factor Rev 18(1-2): 195-207 (Pubitemid 46420552)
9. Caporale A, Brescia A, Galati G, Castelli M, Saputo S, Terrenato I, Cucina A, Liverani A, Gasparrini M, Ciardi A, Scarpini M, Cosenza UM (2007) Locoregional IL-2 therapy in the treatment of colon cancer cell-induced lesions of a murine model. Anticancer Res 27(2): 985-989 (Pubitemid 46587010)
10. Liu K, Rosenberg SA (2003) Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent. J Immunother 26(3): 190-201 (Pubitemid 36686888)
11. Toubaji A, Hill S, Terabe M, Qian J, Floyd T, Simpson RM, Berzofsky JA, Khleif SN (2007) The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine 25(31): 5882-5891 (Pubitemid 47043218)
12. Vaage J (1987) Local and systemic effects during interleukin-2 therapy of mouse mammary tumors. Cancer Res 47(16): 4296-4298
13. Bubenik J, Indrova M, Perlmann P, Berzins K, Mach O, Kraml J, Toulcova A (1985) Tumour inhibitory effects of TCGF/IL-2/-containing preparations. Cancer Immunol Immunother 19(1): 57-61 (Pubitemid 15110997)
14. Meziane K, Bhattacharyya T, Armstrong AC, Qian C, Hawkins RE, Stern PL, Dermime S (2004) Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma. Int J Cancer 111(6): 910-920 (Pubitemid 39096240)
15. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7): 2105-2116 (Pubitemid 29318842)
16. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13(3): 688-696
17. Fisher RI, Coltman CA Jr, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA (1988) Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med 108(4): 518-523
18. Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, Lucas J, Denis-Mize K, Tong B, Navis D, Difrancesco A, Milan S, Wilson SE, Wolin M (2004) Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 10(7): 2253-2264
19. Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P (2004) Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res 10(18 Pt 1): 6101-6110
20. Neelapu SS, Gause BL, Harvey L, Lee ST, Frye AR, Horton J, Robb RJ, Popescu MC, Kwak LW (2007) A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood 109(12): 5160-5163 (Pubitemid 46890531)
21. Neelapu SS, Baskar S, Gause BL, Kobrin CB, Watson TM, Frye AR, Pennington R, Harvey L, Jaffe ES, Robb RJ, Popescu MC, Kwak LW (2004) Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res 10(24): 8309-8317 (Pubitemid 40053391)
22. Falkenberg Frank W, Krup Oliver C (1999) Compositions and methods for treatment of tumors and metastatic diseases. 261816[6406689]. 18-6-2002. 3-2-1999. Ref Type: Patent
23. Krup OC, Kroll I, Bose G, Falkenberg FW (1999) Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation. J Immunother 22(6): 525-538 (Pubitemid 29526348)
24. Agorio C, Schreiber F, Sheppard M, Mastroeni P, Fernandez M, Martinez MA, Chabalgoity JA (2007) Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. J Gene Med 9(5): 416-423
25. Liu D, Yu J, Chen H, Reichman R, Wu H, Jin X (2006) Statistical determination of threshold for cellular division in the CFSE-labeling assay. J Immunol Methods 312(1-2): 126-136 (Pubitemid 44209012)
26. Williams MA, Tyznik AJ, Bevan MJ (2006) Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441(7095): 890-893
27. Waldmann TA (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6(8): 595-601 (Pubitemid 44134092)
28. Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiffer RJ (1993) Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 91(1): 123-132 (Pubitemid 23037263)
29. Kwak LW, Pennington R, Boni L, Ochoa AC, Robb RJ, Popescu MC (1998) Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J Immunol 160(8): 3637-3641 (Pubitemid 28176062)
30. Popescu MC, Robb RJ, Batenjany MM, Boni LT, Neville ME, Pennington RW, Neelapu SS, Kwak LW (2007) A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. Blood 109(12): 5407-5410 (Pubitemid 46890563)
31. Curiel TJ (2008) Regulatory T cells and treatment of cancer. Curr Opin Immunol 20(2): 241-246
32. Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108(3): 804-811
33. Heier I, Hofgaard PO, Brandtaeg P, Jahnsen FL, Karlsson M (2008) Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma. Clin Exp Immunol 152(2): 381-387 (Pubitemid 351520918)
34. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S (2008) Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 93(2): 193-200 (Pubitemid 351397707)
35. Almeida AR, Legrand N, Papiernik M, Freitas AA (2002) Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol 169(9): 4850-4860 (Pubitemid 35217148)
36. Malek TR, Yu A, Vincek V, Scibelli P, Kong L (2002) CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17(2): 167-178
37. Malek TR, Bayer AL (2004) Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4(9): 665-674
38. Nelson BH. (2004) IL-2, regulatory T cells, and tolerance. J Immunol 172(7): 3983-3988
39. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL (2006) Characterization of CD4+ CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24(7): 1169-1177 (Pubitemid 46638815)
40. Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van EK, Schulick R, Pili R (2007) Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 13(15 Pt 1): 4538-4546 (Pubitemid 47219724)
41. Elpek KG, Lacelle C, Singh NP, Yolcu ES, Shirwan H (2007) CD4+ CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol 178(11): 6840-6848 (Pubitemid 46847409)
42. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM (2006) Intratumoral CD4+ CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107(9): 3639-3646